Lavipharm's Annual Shareholders' Meeting was held today, with the required quorum, at the corporate headquarters in Peania. At the opening of the Meeting, Lavipharm's Chairman & CEO, Dr. Athanase Lavidas, referring to the adverse economic situation, highlighted: "Great upheaval occurred in the pharmaceutical field in 2010,...
In a difficult financial environment, with constant changes in the legal framework of the health sector, and especially in pharmaceuticals, Lavipharm has further strengthened its extrovert activities, aiming to an even greater growth of exports. At the same time, the company implemented its long-term plan...
On Saturday, March 27th, all lights and electrical appliances at Lavipharm's headquarters in Peania and at its subsidiaries in Patra, Kavala, Gianenna and Larissa will be turned off for one hour. Lavipharm, participating for the second time in the "Earth Hour", takes this symbolic action...
Consolidated Turnover posted an increase of 5%, reaching Euro 249.8 million compared to Euro 238.0 million during 2008. International Sales have increased by 17%, accounting for 11% of Total Sales. Gross Profit reached Euro 39.5 million from Euro 37.4 million in the last period (+5.6%)....
Lavipharm close to next generation Lavipharm supported once again the Association of Youth Entrepreneurship which the last 8 years cooperates with the country's schools as an educational tool to today's students and future professionals. Through the course of Career Forum, Lavipharm's executives played for a while...
In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses and pharmacies' effort to reduce inventories. As a consequence, Lavipharm's Consolidated Turnover fell to Euro 54.1 million from Euro 59.7 million in Q1...
At the opening of the Meeting, Lavipharm's Chairman & CEO, Dr. Athanase Lavidas, referring to the adverse economic situation, both at national and international level, highlighted: "Within this changing environment, and just before completing our first 100 years of operation, we, at Lavipharm, we promptly...
Although, according to IMS data, sales of medicines from pharmacies to consumers dropped only by 0.4%, the turnover of pharmaceutical companies reported a substantial decline, due to the effort of both wholesalers and pharmacies to exhaust reserves (stock out). In particular, the weighted average decline...
In the context of the ASE regulations and under the 3/347/12.07.05 Board Resolution of Hellenic Capital Market Commission, Lavipharm advises that Mr. Ioannis Alexiades assumes the responsibility of Internal Auditor replacing Mr. Georgios Gemelos. ...
New cooperation between Lavipharm & Pfizer. Pfizer Hellas markets Lavipharm's Dolfen in Greece The product will be promoted by Pfizer's sales force and will be marketed under Lavipharm's trademark Dolfen. Lavipharm already markets the product in Greece since 2007 under the brand name Fentadur. Both Fentadur and...
